""

about | Maps & Directions | contact | admissions | faculty | alumni & development | library | Tech Support Center | dean's office | Policies & Procedures

Office of Clinical Research Administration

OFFICE OF CLINICAL RESEARCH ADMINISTRATION

ACTIVE TRIALS

Bone Marrow Transplant

 

Department: Condition
(as stated in title):
PI Name: IRB #:
Bone Marrow Transplant Hematologic Malignancies Emmons, Robert 12201
IRB Approval Valid Through: December 2010
Status of Trial: Open but closed to enrollment

Bone Marrow Transplant Hematologic Malignancies Emmons, Robert 4471
IRB Approval Valid Through: September 2010
Status of Trial: Open but closed to enrollment

Bone Marrow Transplant Chronic Myeloid Leukemia (CML) Emmons, Robert 11337
A phase II open-label study of the subcutaneous administration of Homoharringtonine (CGX-635) in the treatment of patients with chronic myeloid leukemia (CML) with T3151 BCR-ABL gene mutation (CGX 635-CML-202)
IRB Approval Valid Through: September 2010
Status of Trial: Open but closed to enrollment

Bone Marrow Transplant Chronic Myeloid Leukemia (CML) Emmons, Robert 11338
A phase II open-label study of the subcutaneous administration of Homoharringtonine (CGX-635) in the treatment of patients with chronic myeloid leukemia (CML) who have failed or are intolerant to Tyrosine Kinase Inhibitor Therapy (CGX-6350CML-203)
IRB Approval Valid Through: December 2010
Status of Trial: Open but closed to enrollment

Bone Marrow Transplant AML Emmons, Robert 11426
IRB Approval Valid Through: January 2011
Status of Trial: Open to recruitment

Bone Marrow Transplant Large B-Cell Lymphoma   11664
A phase I study of the monoclonal antibody CT-011 in patients with diffuse Large B-Cell Lymphoma following autologous peripheral blood stem cell transplantation
IRB Approval Valid Through: May 2011
Status of Trial: Open but closed to enrollment

Bone Marrow Transplant Gastrointestinal Graft Disease Martin, Maryellen 12469
A phase I randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of ORBEC (Oral Beciomethasone 17,21-Dippropionate) in conjunction with ten days of high-dose prednisone therapy in the treatment of patients with gastrointestinal graft vs. host disease
IRB Approval Valid Through: August 2010
Status of Trial: Open to recruitment
 

 

Date last updated: 8.05.10